Brief: Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action
27/04/2026 13:33
April 27 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS DELIVERS A MAJOR UPDATE FOR ITS T-CELL ENGAGER PROGRAM REVEALING MECHANISM OF ACTION AND VALIDATING TISSUE FACTOR AS TARGET FOR TREATMENT OF SOLID TUMORS Source text: ID:nGNX2WfGQM Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM